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ABSTRACT 
Exome sequencing in the context of developmental disorders is a useful 
technique, but variants found need to be interpreted in the context of detailed 
phenotypic information. Whole gene deletions and loss-of-function-mutations 
in the HNRNPU gene have been associated with intellectual disability and 
seizures in some patients. However, a unifying syndromic phenotype has not 
been elucidated.   
Here, we report a total of seven patients (six patients identified through 
the Wellcome Trust Deciphering Developmental Disorders study, with one 
additional patient), who have heterozygous de novo mutations in HNRNPU. 
These were found via trio-based exome sequencing. All but one of the 
mutations is predicted to cause loss of function. These patients have 
dysmorphic features in common, including prominent eyebrows, long 
palpebral fissures, overhanging columella and thin upper lip. All patients have 
developmental delay and intellectual disability, ranging from moderate to 
severe. Seizures are common from early childhood. These initially occur in 
the context of febrile episodes.  
This series demonstrates common phenotypic features, including 
emerging dysmorphism, associated with heterozygous HNRNPU mutations. 
This allows us to define a novel neurodevelopmental syndrome, with a likely 
mechanism of haploinsufficiency. 
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INTRODUCTION 
 
Exome sequencing has proven to be an effective tool in the diagnosis 
of rare developmental disorders [Wright et al.,2015]. Increasingly, this method 
is utilised in clinical practice. However, the use of genomic data comes with its 
own challenges. The volume of variants which can be generated necessitates 
sophisticated filtering systems to identify those likely to be pathogenic. This 
means there is an increasing emphasis on detailed and accurate phenotyping 
to enable correct interpretation of sequencing results.  
 
 The importance of this approach can be seen with exome sequencing 
studies of patients with epilepsy [Carvill et al., 2013; de Kovel et al., 2016; 
Epi4K Consortium, 2013]. This condition displays marked genetic 
heterogeneity. Given the rarity of many epilepsy-associated conditions, it can 
be difficult to determine the pathogenicity of variants in genes found using an 
exome-wide testing method. Therefore, identifying a more detailed phenotype 
associated with a particular gene allows for better interpretation of sequencing 
results and more confidence in predictions of pathogenicity.  
 
Overlapping chromosomal microdeletions can be useful in the initial 
identification of phenotypes associated with haploinsufficiency of a particular 
gene. Patients with 1q44 deletions have been described with a phenotype of 
developmental delay (particularly speech), microcephaly, 
hypogenesis/agenesis of the corpus callosum and seizures. Analysis of the 
smallest region of overlap has identified the HNRNPU (Heterogeneous 
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Nuclear Ribonucleoprotein U) gene as a candidate for the epilepsy and 
intellectual disability (ID) phenotype associated with this microdeletion 
[Caliebe et al., 2010; Thierry et al., 2012]. 
 
HNRNPU loss-of-function mutations have been associated with 
epilepsy and developmental delay in individual patients as part of larger 
cohorts [Carvill et al., 2013; de Kovel et al., 2016; Epi4K Consortium, 2013; 
Hamdan et al., 2014; Need et al., 2012]. Recently two series confirming the 
association of HNRNPU mutations with epilepsy and ID have been published 
[Bramswig et al., 2017., Depienne et al., 2017]. However, the phenotypic 
spectrum still remains to be delineated. In particular, a common dysmorphic 
phenotype has not been fully defined.  
 
Here, we report seven patients with de novo mutations in HNRNPU. 
Six of these patients were identified through the Wellcome Trust Deciphering 
Developmental Disorders (DDD) study [Wright et al., 2015] with an additional 
patient identified via MatchMaker exchange [Philippakis et al., 2015]. We 
demonstrate common phenotypic features, including facial dysmorphism, ID, 
seizures, and behavioural problems. This previously undescribed pattern of 
features allows us to define a novel neurodevelopmental syndrome.  
 
MATERIALS AND METHODS 
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Patients one to six were identified through the DDD study. Recruitment 
to this study was via UK regional Clinical Genetics centres after routine 
referral. The affected person and their parents underwent trio-based exome 
sequencing and analysis as previously published [Wright et al,. 2015]. Array-
based comparative genomic hybridization (aCGH) was also used to analyse 
copy number variation. Patient seven was recruited via a local Clinical 
Genetics centre in Melbourne, Australia, and had an uninformative Single 
Nucleotide Polymorphism (SNP) array. For this patient, whole exome 
sequencing and data processing were performed by Genomics Platform at the 
Broad Institute of Harvard and MIT (Broad Institute, Cambridge, MA, USA). 
Whole exome sequencing was performed using Illumina exome capture (38 
Mb target) and the data was processed through a pipeline based on Picard. 
SNPs and insertions/deletions (indels) were jointly called across all samples 
using Genome Analysis Toolkit (GATK) HaplotypeCaller package version 3.4. 
 
RESULTS 
 
Patient reports 
 
Patient One (DECIPHER ID: 258995) 
 
Patient one is a female, born to non-consanguineous parents. The 
family history was unremarkable. The pregnancy was complicated by 
gestational diabetes. She was born at 38 weeks gestation by emergency 
caesarean section. Her birth weight was on the75th centile. She walked 
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independently after the age of two years. Her first words were at the age of 
five years.  
 
On assessment at the age of 15 years, her head circumference was on 
the 75th centile, weight between the 98th and 99.6th centile and height between 
the9th and25th centiles. She had special educational needs, and moderate ID. 
She developed epilepsy at the age of approximately one year. Her seizures 
were frequent, primarily absences, and could be triggered by fevers. 
Dysmorphic features included a short philtrum, thin upper lip, deep-set eyes 
and long eyelashes. Her gait was wide-based and she was noted to have 
hand-flapping movements. Magnetic resonance imaging (MRI) of the brain 
and echocardiogram were normal.  
 
Patient Two (DECIPHER ID: 260453) 
 
Patient two is a male, born to non-consanguineous parents. He was 
noted to have two maternal uncles with mild learning difficulties and a 
maternal cousin with autism. During pregnancy, cardiac abnormalities were 
found on 20-week antenatal ultrasound. He was born at 37-weeks gestation. 
Birth weight was between the2nd and9th centiles. He was found to have 
transposition of the great vessels, tricuspid atresia and a ventricular septal 
defect. He had pulmonary artery banding on the first day of life and has 
subsequently undergone multiple cardiac operations. He walked 
independently, and spoke his first words after the age of two years.  
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He had special educational needs, and has moderate ID.  He was 
noted to be emotionally labile and to anger easily. He did not have any 
seizures or hand-flapping movements. He also developed a brain abscess at 
the age of eight years and had recurrent ear infections. He has been 
diagnosed with Tourette syndrome.  
 
On assessment at the age of 14 years, his head circumference was 
between the 2nd-9th centiles, weight between 9th and 25th centiles and height 
2nd-9th centiles. His facial features were thought to resemble his family. He 
had a left single transverse palmar crease. 
 
He is now attending an adult education college, with learning difficulties 
particularly regarding communication and social skills. He uses a wheelchair 
and scooter for mobility. He cannot walk or propel his wheelchair for long 
distances. 
 
MRI of the brain as a child demonstrated small periventricular areas 
with high T2 signal, thought to be non-specific, but possibly due to previous 
ischaemic events. He was additionally found to have maternal uniparental 
disomy (UPD) of chromosome nine (previously published by King et al., 
2014). It is not certain whether this is significantly contributing to his 
phenotype. 
 
Patient Three (DECIPHER ID: 265865) 
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Patient three is a female, born to non-consanguineous parents. She 
had a paternal cousin with development delay and seizures. The pregnancy 
was complicated by a maternal renal infection. The patient was born at term. 
Birth weight was between the 9th and25th centiles.  
 
She walked independently after the age of four years and her first 
words were at the age of 18 months. She was able to speak a few words by 
the age of three years. She was also noted to be hypotonic as an infant.  
 
She was thought to have autistic traits. She had special educational 
needs and severe ID. She developed epilepsy at the age of one year, initially 
febrile seizures, which have now resolved. On assessment at the age of 12 
years, her height was on the 9th centile and weight on the 96th centile. Her 
head circumference was previously on the 25th centile at the age of three ½ 
years. Dysmorphic features included synophrys with thick eyebrows and a 
short nose. She had hand flapping when excited. Echocardiogram was 
normal.  
 
Patient Four (DECIPHER ID: 268390) 
 
Patient four is a female, born to non-consanguineous parents. Family 
history was unremarkable. The pregnancy was uncomplicated. The patient 
was born at 38 weeks gestation. Birth weight was on the2nd centile.  
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She crawled at two years nine months of age, and walked 
independently at the age of approximately five years. Her first words were at 
around four  years 6 months of age, and she had limited communication with 
Makaton sign language prior to this.  
Drooling has been a long-standing problem. Initially this was treated 
with hyoscine patches, but she required bilateral trans-tympanic 
neuronectomy. This gave a good result initially, but drooling has started to 
worsen again. She has also previously had conductive hearing loss with vent 
insertion.  She had a single seizure at the age of approximately five years. 
She had special educational needs. She displayed good comprehension, but 
her words remained unclear and speech was limited to short sentences.  
 
On assessment at the age of 6 years 6 months, her head 
circumference was on the0.4th centile, weight between the25th and 50th 
centiles, and height 105.6cm between the 0.4th and 2nd centiles.  
 
Dysmorphic features included low-set, posteriorly rotated ears, a mild 
conductive hearing impairment, strabismus, anteverted nares, a prominent 
metopic ridge, epicanthic folds, smooth philtrum, thin vermillion border and 
two-three toe cutaneous syndactyly bilaterally (Fig. 3). She is hypermobile, 
particularly affecting the upper limbs. She had hand-flapping behaviours, and 
a generally pleasant demeanour. She was also myopic. MRI of the brain was 
normal at two years of age.  
 
Patient Five (DECIPHER ID: 277603) 
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Patient five is a female, born to non-consanguineous parents. The 
family history was unremarkable. The pregnancy was uncomplicated. The 
patient was born at 40 weeks gestation. Her birth weight was between the50th 
and 75th centiles.  She walked independently at around two years of age. Her 
first words were after two years.  
 
Her behaviour was aggressive at times, with violent episodes. She also 
had a diagnosis of autism. She had frequent ear infections and constipation. 
She had special educational needs and had severe ID.  
 
She developed frequent absence seizures before the age of one year. 
She also had generalised seizures, usually triggered by fevers, requiring anti-
epileptic medications (Lamotrigine and Topiramate). On assessment at the 
age of 21 years, her head circumference was between the75th and91st 
centiles, weight greater than the99.6th centile, and height between the0.4th 
and2nd centiles.  
 
Dysmorphic features included prominent eyebrows, elongated 
palpebral fissures, epicanthic folds, hypertelorism, brachydactyly, and 
tapering fingers (Fig. 3). She had hand flapping and wringing movements. 
She continues to have occasional absence seizures and remains in a 
specialist centre for autism. 
 
Patient Six (DECIPHER ID: 263453) 
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Patient six is a female, born to non-consanguineous parents. Family 
history was unremarkable. The pregnancy was uncomplicated. The patient 
was born at 42 weeks gestation. Birth weight was on the9th centile. Her 
parents had concerns about her development from four months of age, as she 
had hypotonia and delayed milestones. 
 
She did not walk independently until the age of three years. Her 
speech was delayed, particularly expressive. At age 11 years, she still had no 
formal words, but could communicate through signing and using a picture 
board on a computer pad. She has special educational needs, and attends a 
school for children with severe ID. She has a sociable, loving personality. She 
has repetitive mannerisms, such as hand-flapping movements, particularly 
when excited.  
 
She developed epilepsy with generalised tonic-clonic seizures at the 
age of eight months. These were well-controlled on sodium valproate. Her 
seizures resolved and she was weaned off treatment aged six years.  
 
On assessment at the age of 11 years, her head circumference was on 
the 75th centile, weight on the75th centile,  and height on the 2nd centile. 
Dysmorphic features included thick hair and eyebrows, prognathism, broad 
thumbs and great toes, and truncal obesity. She walked with a wide based 
unsteady gait with hypermobility especially at her ankles requiring supportive 
14 
  Yates et al. 
footwear. MRI brain at the age of one year demonstrated delayed myelination, 
but no other abnormalities. 
 
Patient Seven  
 
Patient seven is a female, born to non-consanguineous parents. Her 
family history was unremarkable. The mother had ovarian stimulation prior to 
pregnancy. This patient is one of a dizygous twin pair. The other twin is 
unaffected. The pregnancy was uncomplicated. This patient was born at 38 
weeks gestation with a birth weight on the0.4th centile. She was admitted to a 
Special Care Baby Unit due to complications related to low birth weight. She 
sat independently at 18 months of age, and walked independently at 6 years 6 
months. Her first words were at three years of age.  
 
On assessment at the age of 8 years 6 months, her head 
circumference was on the2nd to 9th centile, weight on the2nd centile,  and 
height below the 0.4th centile. She did not have any dysmorphic features. She 
had moderate ID. She developed generalised seizures at the age of 18 
months, which were initially triggered by fevers. She was treated with 
Levetiracetam. Her seizures resolved and she was weaned off treatment aged 
five years.  
 
MRI brain scans at the ages of three and seven years showed non-
progressive T2 and FLAIR hypertense lesions involving the deep white matter 
bilaterally, with sparing of the occipital lobes and basal ganglia.  
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Sequencing results 
 
Each patient was found to have a heterozygous de novo mutation in 
HNRNPU (Table I; Fig. 1). Patient Two was also previously noted to have 
complete maternal UPD of chromosome nine [King et al., 2014].  
 
 
 
DISCUSSION 
 
Gene function 
 
HNRNPU is an RNA-binding protein, expressed in brain (particularly 
the cerebellum), heart, kidney and liver [Thierry et al., 2012]. It is largely 
localised to the nucleus, functioning as a mediator of alternative splicing and 
in transcriptional regulation [Geuens et al., 2016]. Reduced expression of 
Hnrnpu results in embryonic lethality in mice [Roshon et al., 2005]. Hnrnpu 
cardiac-specific knockout results in a rapidly progressive dilated 
cardiomyopathy, with widespread dysregulation of splicing [Ye et al., 2015]. 
 
The role of HNRNPU in transcriptional regulation can be mediated 
through an interaction with long noncoding RNA (lncRNA), which are 
increasingly recognised as playing a role in gene expression [Lin et al,. 2017]. 
For example, HNRNPU plays a crucial role in X-inactivation, by enabling 
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chromosomal localisation of the lncRNA Xist as well as being required for 
Xist-mediated function [Hasegawa et al., 2010]. 
 
Hnrnpu has also been shown to give rise to circular RNA (ciRNA), with 
expression almost entirely in neurons. ciRNA have an emerging role in a 
number of areas including regulation of microRNA function and alternative 
splicing [Reddy et al., 2017].  HNRNPU is part of a larger family of hnRNP 
(Heterogeneous Nuclear Ribonucleoproteins). Interestingly, other hnRNP 
have been implicated in neurological disease and cancer [Geuens et al., 
2016], emphasising the wide-ranging functions of these proteins.  
 
HNRNPU-related syndrome 
 
The patient series presented here clarifies and delineates the 
phenotypic features associated with HNRNPU mutations (Table II, Table III). 
Emerging dysmorphism includes a common facial appearance, with 
prominent eyebrows (4/7) elongated palpebral fissures (4/7), a prominent 
nasal bridge (3/7), overhanging columella (4/7) and a thin upper lip (6/7) (Fig. 
2). There are facial changes with age, particularly with regard to the prominent 
nasal bridge (Fig. 3). The oldest patient in our series is now 21 years of age 
(Patient 5), and these changes are especially apparent in her. Of note, there 
are no significant associated complications antenatally, or during the neonatal 
period.   
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There is significant developmental delay in all of the patients presented 
here. Speech appears to be disproportionately affected. Each patient has 
moderate to severe ID. Most have special educational needs (6/7). Epilepsy is 
a frequent finding (5/7), and seizure onset is usually by the age of one year. 
Initial seizure presentation is in the form of febrile seizures progressing to 
afebrile seizures. There does not appear to be a predominance of a particular 
form of seizure with patients presenting with a combination of absences, 
generalised and focal epilepsy. Developmental delay is apparent before the 
onset of seizures.  
 
Two patients had a tendency to aggressive outbursts, with one 
demonstrating some violent behaviours. Interestingly, a patient with similar 
issues, requiring antipsychotic medication, has been reported [Epi4K 
Consortium, 2013]. In addition, 5/7 patients demonstrated hand-flapping 
behaviours. Therefore, behavioural abnormalities may also represent part of 
the HNRNPU-associated phenotype. Of note, diagnoses considered, prior to 
exome sequencing, in some of these patients included Smith-Magenis and 
Angelman syndromes, suggesting behavioural issues are a prominent 
presenting feature. Additionally, some of the patients in this cohort also had 
RAI1 testing as the behavioural phenotype was very suggestive.  
 
One patient in our series (Patient Two) was also found to have 
maternal UPD of chromosome nine [King et al., 2014]. No other variants were 
identified. 7RWKHDXWKRUV¶NQRZOHGJHWKHUHLVQRGHILQLWHHYLGHQFHRI
imprinting on this chromosome, and UPD 9 (mat) has been reported in a 
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phenotypically normal individual [Bjorck et al., 1999]. Therefore, this is not 
thought likely to have a significant impact on phenotype. However, Patient 
Two had a significant cardiac defect and appears to have a more severe 
phenotype than other patients in this series. It remains to be seen if the UPD9 
(mat) is contributing to some of his clinical presentation. 
 
All but one of the patients presented here have mutations predicted to 
result in loss of function. This suggests haploinsufficiency as a likely 
pathogenic mechanism. Indeed, studies of patients with 1q43q44 deletions 
have identified HNRNPU deletion as a possible cause of epilepsy and ID, as 
part of a wider syndrome including microcephaly and central nervous system 
anomalies [Caliebe et al., 2010; Thierry et al., 2012]. More recently, this has 
been confirmed in a series directly comparing the phenotypes of patients with 
1q43q44 microdeletions to those with loss of function HNRNPU mutations 
[Depienne et al., 2017]. This study showed that changes in HNRNPU 
determine the epilepsy phenotype in 1q43q44 syndrome, and have a 
significant influence on the degree of ID.  
 
A recent series of six individuals with HNRNPU mutations also 
demonstrates an ID and epilepsy phenotype [Bramswig et al., 2017]. 
Interestingly, all of these patients have severe ID, in contrast to our cohort in 
which 4/7 patients have moderate learning difficulties. Speech impairment 
was prominent, in keeping with our findings. Two of these patients (individuals 
3 and 4) have similar facial features to those seen in our cohort, further 
delineating the phenotypic spectrum associated with HNRNPU.  
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Three other patients (individuals one, two and six) in the series of 
Bramswig et al. [2017] have more severe craniofacial dysmorphism, including 
dental anomalies, which is not in keeping with our findings. Two of these 
patients (one and six) have missense mutations. Interestingly, the HNRNPU 
mutations found in these individuals are all within the large protein-protein 
interaction domain B30.2/SPRY, indicating a possible genotype-phenotype 
correlation. However, two patients in our cohort (individuals three and six) 
also have mutations within this domain, but do not share the more severe 
phenotype. It is possible that the missense mutations seen in individuals one 
and six from Bramswig et al. [2017] result in an alternate pathogenic 
mechanism compared to the likely haploinsufficiency seen in our cohort. 
Therefore, the significance of these mutations, and the possible clustering in 
B30.2/SPRY, remains to be defined.   
 
In addition, 4/6 individuals in the study of Bramswig et al.  [2017] had 
cardiac abnormalities and 3/4 renal abnormalities. Only one of our patients 
had cardiac abnormalities, and, as discussed, this may be associated with his 
UPD of chromosome 9. None of our patients had renal problems. Our findings 
therefore do not support the association of HNRNPU mutations with cardiac 
and/or renal abnormalities.  
 
CONCLUSION 
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In summary, we present evidence that a neurodevelopmental 
syndrome with features including ID, seizures, behavioural abnormalities, and 
craniofacial dysmorphism, is associated with de novo loss of function 
mutations in HNRNPU. This delineation of the phenotype should aid 
identification of further clinically affected patients and allow for more accurate 
interpretation of results obtained through genomic testing.  
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Patient number HNRNPU mutation Predicted protein 
change 
1 c.1626_1627insA p.(Lys543*) 
2 c.418G>A p.(Glu140Lys) 
3 c.1117+1G>A Splice donor site 
alteration 
4 c.23del p.(Val8Glufs*4) 
5 c.1424_1425insTC p.(Ile476Profs*7) 
6 c.960G>A p.(Trp320*) 
7 c.1664del p.(Leu555Argfs*51) 
 
 
Table I. HNRNPU mutations found in patient series, with predicted protein 
change shown.  
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Patient ID 
(DECIPHER ID) 1 (258995)  2 (260453) 3 (265865) 4 (268390) 5 (277603) 6 (263453) 7 
Total (of features 
reported) 
Genotype c.1626_1627insA c.418G>A c.1117+1G>A c.23del c.1424_1425insTC c.960G>A c.1664del 
- 
Protein change 
(predicted) p.(Lys543*) p.(Glu140Lys) splice donor variant p.(Val8Glufs*4) p.(Ile476Profs*7) p.(Trp320*) p.(Leu555Argfs*51) - 
Inheritance De novo De novo De novo De novo De novo De novo De novo 
- 
Additional genetic 
finding n/a 
Complete UPD (mat) 
chr 9 n/a n/a n/a n/a n/a - 
Age last assessed 15yr 14yr 12yr 6 yrs 5 mths 21yr 11 yr 8 yr 6 months 
- 
Sex F M F F F F F 
- 
Pregnancy NAD Congenital cardiac disease 20 week scan 
Maternal renal 
infection 16 weeks 
gestation 
NAD NAD NAD Ovarian stimulation, dizygotic twins - 
Birth Emergency caesarean 
section NAD NAD NAD NAD NAD NAD - 
Neonatal unit n/a 18 days n/a n/a n/a n/a Yes 
- 
Gestation (weeks) 38 37 40 38 40 42 38 
- 
Feeding Difficulties No Yes  No No No No No 
- 
Additional  
cranio-facial features 
Synophrys, deepset 
eyes, long eyelashes, 
slightly coarse 
Pointed chin 
Low anterior hairline, 
synophrys, 
strabismus, short 
upturned nose, coarse  
Epicanthic folds, low 
set posteriorly rotated 
ears, upturned nose, 
smooth philtrum 
Hypertelorism Thick hair, prognathism n/a - 
Other features 
Puffy dry skin over 
hands and feet, wide 
based gait 
Transposition of the 
great vessels, tricuspid 
atresia, VSD. Left 
single palmar crease 
Spinal lordosis  
Bilateral 2-3 toe 
cutaneous syndactyly, 
hypermobility.  
Brachydactyly, 
tapering fingers 
Broad thumbs and 
great toes, truncal 
obesity 
n/a 
- 
Prominent eyebrows No Yes  Yes No Yes Yes No 4/7 (57%)  
Elongated PF No Yes No Yes Yes Yes No 4/7 (57%) 
Prominent nasal 
bridge  No Yes No No Yes Yes No 3/7 (43%) 
Overhanging 
columella No Yes No Yes Yes Yes No 4/7 (57%) 
Thin upper lip Yes Yes No Yes Yes Yes Yes 6/7 (86%) 
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Patient ID 
(DECIPHER ID) 1 (258995)  2 (260453) 3 (265865) 4 (268390) 5 (277603) 6 (263453) 7 
Total (of features 
reported) 
ID Moderate Moderate Moderate Severe Severe Severe Moderate 7/7 (100%) 
Seizures Yes None Yes Single seizure only Yes Yes Yes 5/7 (71%) 
Age onset of 
seizures 5 years n/a 1 year 5 years <1 year 8 months 18 months n/a 
Febrile seizures Yes No Yes No Yes No Yes 4/7 (57%) 
EE No No No No No No No 0/7 (0%) 
Delayed 
development Yes Yes Yes Yes Yes Yes Yes 7/7 (100%) 
Sat independently 9 months 10 months 18 months 2-2.5yr 15 months 15 months 18 months n/a 
Walked independently 2-2.5yr 2-2.5yr 4-5yr Just before 5 years 22 months 39 months 6.5 years n/a 
First words 5 years and over 2-2.5yr 18 months 5 years 2-2.5 years not achieved aged 11 yr 3 years n/a 
Behaviour n/a Angers easily, Tourette syndrome Autism traits Very sociable 
Aggression with 
violent episodes Very sociable n/a n/a 
Hand flapping Yes No Yes Yes Yes Yes No 5/7 (71%) 
Special educational 
needs Yes Yes Yes Yes Yes Yes 
Mainstream school 
with additional support 6/7 (86%) 
Cranial MRI 
abnormal* No Yes* No No No n/a Yes* 2/7 (29%) 
Table II. Features of patients with de novo mutations in HNRNPU. Includes patients in case series presented as well as 
previously reported cases. Of note, patient in Need et al., 2012 not included as patient has additional variant and 
complex phenotype not accounted for by HNRNPU mutation. *MRI abnormalities: Patient 2 - Small periventricular areas 
with high T2 signal; Patient 7 - Non-progressive T2 and FLAIR hyperintensities in white matter bilaterally.  
 
Abbreviations: EE ± epileptic encephalopathy. ID ± intellectual disability. n/a: not applicable. NAD: no abnormalities detected. n/r: not reported. PF ± palpebral fissures. UPD: uniparental disomy. VSD ± 
ventricular septal defect.  
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Clinical 
features 
This study 
cohort 
Depienne et 
al. (2017) 
Bramswig et 
al. (2017) 
de Kovel et al. 
(2016) 
Epi 4K-
Consortium 
(2013) 
Carvill et al. 
(2013) 
Need et al. 
(2012) 
Total (of 
reported 
features) 
Distinct facial 
appearance 
 6/7 n/r 6/6 1/1 0/1 n/r n/r 13/15 (87%) 
ID 7/7  7/7 6/6 n/r 1/1 1/1 1/1 23/23 (100%) 
Seizures 5/7  6/7 6/6 1/1 1/1 1/1 1/1 21/24 (88%) 
Seizure onset 
prior to five 
years age 
6/6 6/6 5/5 1/1 1/1 1/1 n/r 20/20 (100%) 
Febrile 
seizures 
4/7  5/6 2/5 1/1 1/1 0/1 n/r 13/21 (62%) 
Delayed 
development 
7/7  7/7 5/5 1/1 1/1 1/1 n/r 22/22 (100%) 
Speech 
impairment 
6/7 7/7 6/6 1/1 1/1 n/r n/r 21/22 (95%) 
Hand flapping 5/7  1/7 1/6 n/r n/r n/r n/r 7/20 (35%) 
MRI Abnormal 
MRI-brain 
2/7  3/5 4/4 1/1 1/1 n/r n/r 11/18 (61%) 
Table III. Comparison of features in individuals with HNRNPU mutations compared with 
those reported in the literature. Note the patient previously reported by Hamdan et al. (2014) 
has been described in more detail by Bramswig et al.  
 
Abbreviations: ID ± intellectual disability. n/a: not applicable.. n/r: not reported. PF ± palpebral fissures.  
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